KRAS and malignant colon neoplasm: In preclinical models, inhibition of DHODH has been shown to increase the efficacy of chemotherapy by significantly enhancing cell death in pancreatic tumors refractory to therapies or ovarian, lung, pancreatic, and colon cancer cells with oncogenic Kras [17,18].